SL-701 Demonstrates Antitumor Activity in Relapsed/Refractory GBMJune 27th 2018
The anticancer immunotherapy vaccine SL-701, when used with immunostimulants, induced antitumor activity in patients with relapsed/refractory glioblastoma both alone and in combination with bevacizumab, according to updated phase II results from the 2-stage STML-701-0114 trial presented at the 2018 ASCO Annual Meeting.
Sustained Survival Rates Seen With Oncolytic Poliovirus in Patients With Recurrent GBMJune 26th 2018
According to phase I findings recently published in the<em> New England Journal of Medicine, </em><sup> </sup>the recombinant oncolytic poliovirus PVSRIPO demonstrated a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.
Carboxyamidotriazole Orotate Demonstrates Promising Efficacy in Brain CancersApril 28th 2018
In a recent phase Ib study, the combination of carboxyamidotriazole orotate (CTO) and temozolomide (Temodar) produced positive safety and efficacy results in patients with glioblastoma (GBM) or anaplastic gliomas, with or without treatment with radiotherapy.
Investigating TTFields for Treatment of Newly Diagnosed GlioblastomaApril 25th 2018
Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.